Recruiting
Phase 3

TH07

Sponsor:

Triple Hair Inc

Code:

NCT07435012

Conditions

Androgenic Alopecia

Eligibility Criteria

Sex: Male

Age: 18 - 49

Healthy Volunteers: Not accepted

Interventions

TH07

TH07

Minoxidil 5% Topical Solution

Placebo

Study Details

Brief summary:

The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.

Conditions

Androgenic Alopecia

Study ID

NCT07435012

Start date

Apr, 2026

Status verified date

Mar, 2026

Completion date

Apr, 2028

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18 - 49

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Males, 18 to 49 years of age on the date of enrollment.
  • Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.
  • Body Mass Index (BMI) in the range of 19 to 35 kg/m2.
  • Not administered any systemic or topical treatment for AGA during the last 90 days.
  • Willing to comply with the following restrictions for the duration of trial participation:

1. Any systemic or topical treatment of any system of medicine (other than trial treatment) for AGA.
2. Hair dyes, hair texturizers, relaxers etc.
3. Any new vitamins or nutritional supplements that are currently not being administered.
4. Tattooing in the trial target area.
5. Blood donations.
6. OTC hair restorers.
7. Do not expose your pregnant partner to your hands/skin where the drug might be present.
8. Participation in any other drug or device trials during the course of this trial.

Note: However, the following shall be permissible:
9. Non-medicated \& anti-dandruff shampoos, scalp/hair applications including styling gels, sprays, mousse (styling gels, sprays, mousse etc. not to be used on the days of trial visits to the clinic.
10. Current regimen (if any) of vitamins and nutritional supplements.
  • Willing and able to provide written informed consent for participation in the trial and to comply with all trial requirements.
  • Availability of and usage familiarity with a personal mobile phone (Android or iOS) with internet connectivity and a personal email address.

Exclusion Criteria:

  • History of scalp treatment including though not limited to any of the following:

1. Hair transplant or extension surgery.
2. Hair weaving.
3. Laser or light therapy on the scalp in the last 6 months.
4. Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months.

5-Any other surgical treatment for hair loss
  • Any of the following hair styles:

1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.
  • Known or presumed hypersensitivity to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigator may affect the outcome of trial.
  • Any other significant abnormalities indicating of severe, acute or chronic medical condition(s) that may lead to hair loss or otherwise interfere with the interpretation of trial results.
  • History or likelihood of use of any of the specified medicines.
  • History or clinical diagnosis of any of the specified medical conditions.
  • Participation in any investigational or marketed drug or device trial in the last 90 days prior to screening for this trial.
  • Any other condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the trial.

Study Design

Enrollment

420 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Arm A

All participants in Arm A will apply TH07 topical solution twice a day for 24 weeks

experimental: Arm B

All participants in Arm B will apply TH07 topical solution once a day and Placebo topical solution once a day for 24 weeks

active comparator: Arm C

All participants in Arm C will apply Minoxidil 5% topical solution twice a day for 24 weeks

placebo comparator: Arm D

All participants in Arm D will apply Placebo topical solution twice a day for 24 weeks

Interventions

TH07

TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day

TH07

  • TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day
  • Placebo; topical solution; once a day

Minoxidil 5% Topical Solution

Minoxidil 5%; topical solution; twice a day

Placebo

Placebo; topical solution; twice a day

Primary outcome measure

  • Non-vellus hair count [ Time Frame: Baseline and week 24 ]

Central Contacts and Locations

Central contacts

Locations

YVR Aesthetic Training and Study Centre.

Recruiting

Vancouver, British Columbia, Canada, V5Z1H2

Contacts

More Information

Sponsor

Triple Hair Inc

Last update posted

Mar 16, 2026

Last verified

Mar, 2026

Keywords

  • Hair Loss
  • Hair growth
  • Androgenic Alopecia
  • Balding

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-26. This information was provided to ClinicalTrials.gov by Triple Hair Inc on 2026-03-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.